Evaluation of immunotherapies improving macrophage anti-tumor response using a microfluidic model
Organs-on-a-Chip · 2022
DOI: 10.1016/j.ooc.2022.100019 ↗Kurz gefasst
Fachartikel in der Zeitschrift Organs-on-a-Chip, 2022. Verfasst von Mariya Chernyavska und 7 weiteren Autor:innen. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Tumor-on-a-chip models are rapidly coming to the fore as a promising platform to accurately mimic tumor biology. These models overcome ethical concerns of animal usage in research, and are of particular use in the field of immuno-oncology, as there are substantial interspecies differences in how cells of the immune system operate. Additionally, they allow a human-centered investigation of novel immunotherapeutic approaches. Here, we report a new application of a microfluidic tumor-on-a-chip system and show its utility by investigating macrophage responses in the context of a promising therapeutic approach that combines anti-epidermal growth factor receptor (EGFR) IgA with an anti-CD47 innate immune checkpoint inhibitor. We report a novel on-chip microscopy-based antibody-dependent cellular phagocytosis (ADCP) assay with human M1-like pro- or M2-like anti-inflammatory macrophages and tumor cells in a collagen matrix. The tumor microenvironment was further characterized by ELISA for secreted factors in the culture medium and through endpoint analyses of gene expression by RT-qPCR. Employing the novel on-chip assay, we show for the first time that the combination of anti-EGFR IgA and a CD47 checkpoint inhibitor synergistically activate macrophage phagocytic function to specifically kill cancer cells, especially for M2-like macrophages. We further demonstrate that the checkpoint inhibition is responsible for elevated secretion of inflammatory cytokines such as TNFα and IL-6, and tends to elevate expression of genes regulating both inflammation (IL-1β) and phagocytic function (CD209), particularly in M2-like macrophages. Taken together, we demonstrate a novel on-chip ADCP assay compatible with multi-parameter characterization of the tumor microenvironment on-chip and demonstrate its utility for yielding novel insights regarding innate immunotherapy combinations.
Zitieren
APA
Chernyavska, M., Hermans, C. K., Chan, C., Baumann, N., Rösner, T., Leusen, J. H., Valerius, T., & Verdurmen, W. P. (2022). Evaluation of immunotherapies improving macrophage anti-tumor response using a microfluidic model. Organs-on-a-Chip. https://doi.org/10.1016/j.ooc.2022.100019
Vancouver
Chernyavska M, Hermans CK, Chan C, Baumann N, Rösner T, Leusen JH, et al. Evaluation of immunotherapies improving macrophage anti-tumor response using a microfluidic model. Organs-on-a-Chip. 2022. doi:10.1016/j.ooc.2022.100019
BibTeX
@article{Chernyavska2022,
author = {Chernyavska, Mariya and Hermans, Charlotte K.J.C. and Chan, Chilam and Baumann, Niklas and Rösner, Thies and Leusen, Jeanette H.W. and Valerius, Thomas and Verdurmen, Wouter P.R.},
title = {Evaluation of immunotherapies improving macrophage anti-tumor response using a microfluidic model},
journal = {Organs-on-a-Chip},
year = {2022},
doi = {10.1016/j.ooc.2022.100019}
}
EUVIMED